vs

Side-by-side financial comparison of PEOPLES BANCORP OF NORTH CAROLINA INC (PEBK) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

PEOPLES BANCORP OF NORTH CAROLINA INC is the larger business by last-quarter revenue ($21.5M vs $11.2M, roughly 1.9× Verastem, Inc.). PEOPLES BANCORP OF NORTH CAROLINA INC runs the higher net margin — 30.8% vs -876.3%, a 907.2% gap on every dollar of revenue.

PEOPLES BANCORP OF NORTH CAROLINA INC is a regional bank holding company headquartered in North Carolina, U.S. It offers a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving local residents, small and medium-sized enterprises, and community organizations across its operating areas in North Carolina.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

PEBK vs VSTM — Head-to-Head

Bigger by revenue
PEBK
PEBK
1.9× larger
PEBK
$21.5M
$11.2M
VSTM
Higher net margin
PEBK
PEBK
907.2% more per $
PEBK
30.8%
-876.3%
VSTM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PEBK
PEBK
VSTM
VSTM
Revenue
$21.5M
$11.2M
Net Profit
$6.6M
$-98.5M
Gross Margin
Operating Margin
40.7%
-362.2%
Net Margin
30.8%
-876.3%
Revenue YoY
5.6%
Net Profit YoY
86.4%
-311.1%
EPS (diluted)
$1.21
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PEBK
PEBK
VSTM
VSTM
Q4 25
$21.5M
Q3 25
$21.4M
$11.2M
Q2 25
$20.7M
$2.1M
Q1 25
$20.0M
Q4 24
$20.4M
Q3 24
$20.5M
$0
Q2 24
$20.1M
$10.0M
Q1 24
$19.8M
Net Profit
PEBK
PEBK
VSTM
VSTM
Q4 25
$6.6M
Q3 25
$3.7M
$-98.5M
Q2 25
$5.2M
$-25.9M
Q1 25
$4.3M
Q4 24
$3.6M
Q3 24
$4.0M
$-24.0M
Q2 24
$4.9M
$-8.3M
Q1 24
$3.9M
Operating Margin
PEBK
PEBK
VSTM
VSTM
Q4 25
40.7%
Q3 25
22.4%
-362.2%
Q2 25
32.2%
-2047.9%
Q1 25
28.2%
Q4 24
22.5%
Q3 24
26.0%
Q2 24
31.3%
-182.8%
Q1 24
23.9%
Net Margin
PEBK
PEBK
VSTM
VSTM
Q4 25
30.8%
Q3 25
17.2%
-876.3%
Q2 25
24.9%
-1213.6%
Q1 25
21.8%
Q4 24
17.5%
Q3 24
19.3%
Q2 24
24.4%
-82.6%
Q1 24
19.9%
EPS (diluted)
PEBK
PEBK
VSTM
VSTM
Q4 25
$1.21
Q3 25
$0.67
$-1.35
Q2 25
$0.95
$-0.62
Q1 25
$0.79
Q4 24
$0.65
Q3 24
$0.72
$-0.60
Q2 24
$0.89
$-0.31
Q1 24
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PEBK
PEBK
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$58.1M
$137.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$157.1M
$-15.5M
Total Assets
$1.7B
$176.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PEBK
PEBK
VSTM
VSTM
Q4 25
$58.1M
Q3 25
$137.7M
Q2 25
$164.3M
Q1 25
Q4 24
$59.3M
Q3 24
$73.2M
$113.2M
Q2 24
$83.4M
Q1 24
Total Debt
PEBK
PEBK
VSTM
VSTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$40.5M
Q2 24
$40.3M
Q1 24
Stockholders' Equity
PEBK
PEBK
VSTM
VSTM
Q4 25
$157.1M
Q3 25
$149.5M
$-15.5M
Q2 25
$144.0M
$36.1M
Q1 25
$138.5M
Q4 24
$130.6M
Q3 24
$136.3M
$11.1M
Q2 24
$124.3M
$18.9M
Q1 24
$121.1M
Total Assets
PEBK
PEBK
VSTM
VSTM
Q4 25
$1.7B
Q3 25
$1.7B
$176.9M
Q2 25
$1.7B
$196.3M
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.7B
$126.4M
Q2 24
$1.7B
$105.7M
Q1 24
$1.7B
Debt / Equity
PEBK
PEBK
VSTM
VSTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.66×
Q2 24
2.14×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PEBK
PEBK
VSTM
VSTM
Operating Cash FlowLast quarter
$21.4M
$-36.2M
Free Cash FlowOCF − Capex
$20.0M
FCF MarginFCF / Revenue
92.7%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
3.22×
TTM Free Cash FlowTrailing 4 quarters
$34.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PEBK
PEBK
VSTM
VSTM
Q4 25
$21.4M
Q3 25
$4.7M
$-36.2M
Q2 25
$5.5M
$-32.7M
Q1 25
$5.9M
Q4 24
$20.6M
Q3 24
$4.9M
$-23.8M
Q2 24
$6.7M
$-27.6M
Q1 24
$3.7M
Free Cash Flow
PEBK
PEBK
VSTM
VSTM
Q4 25
$20.0M
Q3 25
$4.4M
Q2 25
$5.4M
Q1 25
$5.2M
Q4 24
$20.0M
Q3 24
$4.7M
Q2 24
$6.6M
$-27.6M
Q1 24
$3.5M
FCF Margin
PEBK
PEBK
VSTM
VSTM
Q4 25
92.7%
Q3 25
20.4%
Q2 25
25.9%
Q1 25
25.8%
Q4 24
98.0%
Q3 24
22.9%
Q2 24
32.7%
-275.8%
Q1 24
17.9%
Capex Intensity
PEBK
PEBK
VSTM
VSTM
Q4 25
6.6%
Q3 25
1.5%
Q2 25
0.5%
Q1 25
3.8%
Q4 24
2.9%
Q3 24
1.0%
Q2 24
0.4%
0.1%
Q1 24
0.6%
Cash Conversion
PEBK
PEBK
VSTM
VSTM
Q4 25
3.22×
Q3 25
1.27×
Q2 25
1.06×
Q1 25
1.36×
Q4 24
5.78×
Q3 24
1.24×
Q2 24
1.36×
Q1 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons